Essex Bio-Technology Limited released its earnings results on Aug 26, 2025. The company reported HK$0.288 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.288.

Is Essex Bio-Technology Limited overvalued?

According to Wall Street analysts Essex Bio-Technology Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Essex Bio-Technology Limited pay dividends?

Essex Bio-Technology Limited pays a Quarterly dividend of HK$0.07 which represents an annual dividend yield of 3.42%. See more information on Essex Bio-Technology Limited dividends here

What is Essex Bio-Technology Limited’s EPS estimate?

Essex Bio-Technology Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Essex Bio-Technology Limited have?

Essex Bio-Technology Limited has 567,006,000 shares outstanding.

What happened to Essex Bio-Technology Limited’s price movement after its last earnings report?

Essex Bio-Technology Limited reported an EPS of HK$0.288 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.876%.

Which hedge fund is a major shareholder of Essex Bio-Technology Limited?

Currently, no hedge funds are holding shares in HK:1061

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Essex Bio-Technology Stock Smart Score

Neutral

Analyst Consensus

Hold

Average Price Target:
― (―)

Technicals

Fundamentals

Return on Equity

14.60%

Trailing 12-Months

Asset Growth

9.04%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Essex Bio-Technology Limited

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.